Weed Is More Popular Than the Politicians Running From It
Voters keep saying yes to cannabis. Most candidates in both parties still won't say it back.
Every weekend, Iowans cross the Mississippi into Illinois or head south into Missouri, buy legal cannabis, and hand the sales tax to a state that isn’t theirs. Iowa gubernatorial candidate Rob Sand has built part of his campaign around that scene: “Right now, Iowans are driving over the border to purchase regulated, taxed cannabis in our neighboring states,” he says, pitching a plan to legalize, tax, and regulate weed the way Iowa already regulates alcohol.
He’s not staking out fringe territory. He’s picking up a position most of the field left on the table.
Cannabis is more popular than the politicians who keep dodging it.
That’s the real thread in CNBC’s look at cannabis as a 2026 midterm issue — not that reform is on the ballot in Massachusetts and Idaho this fall, but that on this one issue, voters are running well ahead of the candidates asking for their votes. A statewide Kansas survey found 70% support for medical cannabis and 59% for recreational legalization, with recreational use pulling a plurality of Republicans too. Four of the five Republicans running for governor oppose legalizing it anyway.
That gap — what voters will tell a pollster versus what their own party’s candidates will say from a podium — is the actual story. Cannabis isn’t a live debate anymore in most of the country. It’s a settled position politicians are still too spooked to say out loud.
Massachusetts shows what happens when a state assumes that settlement holds. Voters legalized recreational cannabis in 2016; the industry now generates hundreds of millions in tax revenue a year. In June, the state’s highest court cleared a rollback measure for the November ballot — funded by an out-of-state anti-legalization group — that would kill recreational sales while stripping the equity grants and community agreements built into the current law. A decade of normal didn’t make the law harder to repeal. It just meant nobody kept defending it.
Idaho is running the opposite trap. The state could become the 42nd to legalize medical cannabis this November, a decade behind most of its neighbors — a real win for patients. But unable to stop the measure directly, Idaho lawmakers passed House Joint Resolution 4, a companion constitutional question landing on the same ballot that would hand all future marijuana policy to the legislature alone — retiring, for good, the citizen-petition process that got medical cannabis this close in the first place. Idahoans could win the drug this year and lose the tool that won it, in the same trip to the polls.
None of this is happening because cannabis got riskier or more controversial. It’s happening because legalization stopped being a debate about the drug and became a test of which politicians will say what their own voters already believe. Follow how these fights land in Rize’s policy coverage.
Sand said the quiet part on the record. Four Kansas Republicans are betting their voters won’t remember he was right.
Sources Cited
- 01.A
- 02.B
- 03.B
- 04.B
- 05.CRob Sand's Plan to Legalize, Tax, and Regulate Adult-Use CannabisRob Sand for Iowa
Filed Under
policysocial-culturaltrendsDrug Scheduling
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Cannabis Just Split Into Two Different Drugs — And the Label Doesn't Tell You Which One You're Buying
Federal rescheduling edges closer and blue-state voters keep crushing repeal campaigns, while DEA and state regulators race to purge the synthetic cannabinoids that were invented to dodge cannabis law in the first place.
Policy & FundingThe FDA Isn't Just Approving Nicotine Pouch Flavors — It's Approving Big Tobacco's Next Business Model
The FDA authorized four new flavored 'on!' nicotine pouches this month through its pilot review program, while Big Tobacco's own numbers show pouches are its bet on replacing cigarettes — built on the same discreetness and flavor appeal that make them easy for teens to use undetected.
Policy & FundingMethadone Clinics Loosened the Rules and Retention Jumped 17%. HHS's New Toolkit Buries That.
HHS's new 'Treatment First' toolkit sidelines methadone and buprenorphine and attacks Housing First just as data show flexible dosing reforms raised three-month retention 17% at clinics nationwide.